1.
The effects of bovine colostrum supplementation on in vivo immunity following prolonged exercise: a randomised controlled trial.
Jones, AW, March, DS, Thatcher, R, Diment, B, Walsh, NP, Davison, G
European journal of nutrition. 2019;58(1):335-344
-
-
-
Free full text
-
Plain language summary
Upper respiratory tract symptoms (URS) are the most common ailment reported by athletes to medicine clinics at major sporting events. The main aim of this study was to investigate the effects of bovine colostrum (COL) supplementation on the induction of invivo immune responses to a novel antigen, diphenylcyclopropenone (DPCP) [a topically administered experimental drug], following prolonged exercise. The study is a double-blind randomised placebo-controlled trial which recruited 34 healthy male participants aged between 18 and 45 years. The participants were randomly assigned to one of the two groups: COL group (n = 17) or placebo group (n = 17). Results indicate that COL did not significantly affect the overall response to the novel antigen, DPCP, but COL supplementation induced greater sensitivity of antigen-specific memory recalled 4 weeks following the initial sensitisation. Authors conclude that their findings may suggest a nutritional strategy to counter exercise-induced immunodepression assessed via an established, clinically relevant in vivo marker of immunity.
Abstract
BACKGROUND Bovine colostrum (COL) has been advocated as a nutritional countermeasure to exercise-induced immune dysfunction, but there is a lack of research with clinically relevant in vivo measures. AIM: To investigate the effects of COL supplementation on in vivo immunity following prolonged exercise using experimental contact hypersensitivity (CHS) with the novel antigen diphenylcyclopropenone (DPCP). METHODS In a double-blind design, 31 men were randomly assigned to COL (20 g/day) or placebo (PLA) for 58 days. Participants ran for 2 h at 60% maximal aerobic capacity on day 28 and received a primary DPCP exposure (sensitisation) 20 min after. On day 56, participants received a low-dose-series DPCP challenge to elicit recall of in vivo immune-specific memory (quantified by skinfold thickness 24 and 48 h later). Analysis of the dose-response curves allowed determination of the minimum dose required to elicit a positive response (i.e., sensitivity). RESULTS There was no difference in summed skinfold thickness responses between COL and PLA at 24 h (p = 0.124) and 48 h (p = 0.405). However, sensitivity of in vivo immune responsiveness was greater with COL at 24 h (p < 0.001) and 48 h (p = 0.023) with doses ~ twofold greater required to elicit a positive response in PLA. CONCLUSIONS COL blunts the prolonged exercise-induced decrease in clinically relevant in vivo immune responsiveness to a novel antigen, which may be a mechanism for reduced illness reports observed in the previous studies. These findings also suggest that CHS sensitivity is highly relevant to host defence.